Thymosin Beta-4 Dosage, half-life & reference guide

Week by week.

What to expect in the first 8 weeks

1. Day 1–14Clinical

   The full protein, not the fragment

   Unlike TB-500, you're running the whole thymosin beta-4 protein, which carries its full set of signals: actin regulation, cell migration and anti-inflammatory activity in lab studies. Commonly reported: little change in the first two weeks, sometimes a day of tiredness after a dose.

   The science

   Full-length Tβ4 (43 amino acids) contains the complete actin-binding domain and additional signaling sequences absent in the TB-500 fragment. It regulates actin polymerization, promotes cell migration to wound sites, and activates anti-inflammatory pathways via NF-κB modulation.

   Sources

   • Goldstein et al. (2012)
   • Crockford et al. (2010)

   Updated Apr 2026

2. Day 14–28Community

   Weeks 2 to 4: how the injury responds

   Commonly reported in weeks 2 to 4: less nagging pain and stiffness, especially in older injuries, and easier recovery between sessions. It helps repair cells move in and new blood vessels form. How the injury handles load is your best read.

   The science

   In rats with skin wounds, thymosin beta-4 increased new blood vessels at days 4 and 7 (Malinda 1999). The one published heart-attack trial, a 2025 phase 2 of IV recombinant thymosin beta-4 in 96 patients, found no overall reduction in infarct size, though the 43 patients dosed within 8 hours of their procedure had smaller infarcts (Zhang 2025). No trial has tested injected thymosin beta-4 for injuries.

   Sources

   • Malinda et al. (1999)
   • Zhang et al. (2025)

   Updated Sep 2026

3. With BPC-157Community

   Full Tβ4 + BPC-157: local plus body-wide

   BPC-157 works on local repair at the injury site, while full thymosin beta-4 helps repair cells move in from further afield. Commonly reported: faster recovery from stubborn soft-tissue injuries.

   The science

   BPC-157 acts through VEGFR2/nitric oxide signaling (local angiogenesis); thymosin beta-4 through actin regulation and cell migration. Both rest mostly on animal work. No study has combined full thymosin beta-4 with BPC-157; the one combination test, the TB-500 fragment with BPC-157 in 32 rats, found no added benefit over either alone (Biçer 2026).

   Sources

   • Goldstein et al. (2012)
   • Sikiric et al. (2018)
   • Biçer et al. (2026)

   Updated Sep 2026

4. Any dayClinical

   What full Tβ4 is built on

   Full-length thymosin beta-4 has more human research than the TB-500 fragment: small phase 2 trials of eye drops for dry eye and a gel for leg ulcers, plus IV safety studies. Injected use for injuries hasn't been tested in people; that rests on animal studies and user reports, and there's less community experience than with TB-500.

   The science

   Phase 2 trials: dry eye (eye drops, 9 patients, improved signs and symptoms; Sosne 2015) and venous leg ulcers (topical, 73 patients, "may have the potential to accelerate wound healing"; Guarnera 2010). IV phase 1 in healthy volunteers found it well tolerated (Ruff 2010). A 2025 phase 2 of IV recombinant thymosin beta-4 in 96 heart-attack patients found no overall reduction in infarct size, though the 43 dosed within 8 hours of their procedure had smaller infarcts (Zhang 2025). The full protein retains signaling domains that the TB-500 fragment lacks.

   Sources

   • Sosne et al. (2015)
   • Guarnera et al. (2010)
   • Ruff et al. (2010)
   • Zhang et al. (2025)

   Updated Sep 2026

Swipe for more ›

Mixing and a typical run.

Safety.

Goes with.

• BPC-157
• GHK-Cu

Compared with.

• TB-500 vs Thymosin Beta-4

Questions people ask.

Research.

Reference.

Cadence

Weekly

Half-life

~0.5–2 hours

~0.5–2 hours (given IV to healthy volunteers)

Research basis

●●● Emerging

Primarily preclinical / limited human data